Bibliography
- ELIOT L, LOEWEN G, BUTLER J et al: Steady-state pharmacokinetic comparison of a new, once-daily, extended-release morphine sulfate formulation and immediate-release morphine oral solution in healthy male subjects. 17th Annual Meeting of the American Academy of Pain Medicine, Miami Beach, Florida, USA(February 14 — 18 (2000) (Abstract 205).
- PORTENOY R, SCIBERRAS A, ELIOT L et al.: Steady-state pharmacokinetic comparison of a new extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate to severe pain. .1. Pain Symptom Manage. (2002) 23:292–300.
- ELIOT L, GEISER R, LOEWEN G: Steady-state pharmacokinetic comparison of a new, once-daily extended-release morphine formulation (Morphelan) and Oxycontin® twice daily. I Oncol Pharm. Pract.(2001) 7(1):1–8.
- ELIOT L, CATO A, GEISER R, LOEWEN G: Evaluation of two loading-dose regimens of Morphelan® inhealthy volunteers. J. Applied Res. (2002) 2:1–10.
- ELIOT L, LOEWEN G, BUTLER J et al: "Sprinkle dosing" of a new, once-a-day oral morphine extended-release formulation, Morphelan'" ROEIr. Proceedings of the American Society of Clinical Oncology San Francisco, California, USA(May 12— 15 2001).
- DOUGLAS MD, GARLAND WT, KELLY JB et al.: Efficacy of a new, once-daily rapid-onset, extended-release morphine formulation (Morphelan."" ROER) and a twice-daily morphine sulfate controlled-release formulation(MS Contin®) in patients with chronic, moderate to severe pain. 20-h Annual Scientific Meeting of the American Pain Society Phoenix, Arizona, USA(April 19 — 22 2001) (Abstract 780).
- WYNN D, RAUCK R, COOK D et al: Long-term, open-label safety and efficacy evaluation of a new, oral, once-daily, extended-release morphine sulfate formulation (Avinza'", formerly known as Morphelan). International Association for the Study of Pain, la-h World Congress onPain, San Diego, USA (August 17 — 22 2002).
- CALD WELL JR, RAPOPORT RJ, DAVIS JC et al.: Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial.Pain Symptom Manage. (2002) 23:278–291.
- CALD WELL JR, DAVIS JC,OFFENBERG HL et al.: Efficacy of a new, once-daily, rapid-onset, extended-release morphine formulation and twice-daily MS Contin® on sleep variables in patients with chronic, moderate-to-severe osteoarthritis pain. Od World Congress of World Institutes of Pain, Istanbul, TurkeyJune 27 —30 (2001) (Abstract PTR10).
- LIGAND PHARMACEUTICALS. Unpublished data.